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Background: A recent case-controlled study reported an increased risk of diabetes mellitus in
patients treated with inhaled corticosteroids for asthma or COPD, versus age-matched
controls.
Objective: The purpose of the current study was to evaluate whether there was an increased
risk of new onset diabetes mellitus or hyperglycaemia among patients with asthma or COPD
treated with inhaled corticosteroids.
Methods: A retrospective analysis evaluated all double-blind, placebo-controlled, trials in
patients 4 years of age involving budesonide or budesonide/formoterol in asthma (26 trials;
budesonide: nZ 9067; placebo: nZ 5926), and in COPD (8 trials; budesonide: nZ 4616; non-
ICS: n Z 3643). A secondary dataset evaluated all double-blind, controlled trials in asthma
involving the use of inhaled corticosteroids (60 trials; budesonide: n Z 33,496; fluticasone:
n Z 2773).
Results: In the primary asthma dataset, the occurrence of diabetes mellitus/hyperglycae-
mia adverse events (AEs) was 0.13% for budesonide and 0.13% for placebo (HR 0.98 [95%
CI: 0.38e2.50], p Z 0.96) and serious adverse events (SAEs) was 0% for budesonide and
0.05% for placebo. In the secondary dataset, the occurrence of diabetes/hyperglycaemia
as AE and SAE was 0.19% and 0.03%, respectively. In the COPD dataset, the occurrence of
diabetes mellitus/hyperglycaemia AEs was 1.3% for budesonide and 1.2% for non-ICS (HR
0.99 [95% CI: 0.67e1.46], p Z 0.96) and SAEs was 0.1% for budesonide and 0.03% for
non-ICS.cMaster University Medical Center, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada. Tel.:
2.
r.ca (P.M. O’Byrne).
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1488 P.M. O’Byrne et al.Conclusion and clinical relevance: Treatment with inhaled corticosteroids in patients with
asthma or COPD was not associated with increased risk of new onset diabetes mellitus or
hyperglycaemia.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are the mainstay of treatment
for patients with asthma1,2 and are an important part of the
management of patients with chronic obstructive pulmo-
nary disease (COPD), particularly those who have recurrent
exacerbations.3 While oral glucocorticosteroids may
contribute in a dose-dependent manner to hyper-
glycaemia/impaired glucose tolerance and diabetes melli-
tus in vulnerable patients, the systemic concentrations
achieved during ICS treatment for asthma or COPD are
thought to be too low to affect plasma glucose in most
patients. However, a large nested case-controlled study,
involving patients treated with ICS for asthma or COPD,
reported a 34% increase in the incidence of diabetes mel-
litus over 5.5 years of follow-up versus age-matched
controls who were not treated with ICS.4 By contrast, two
other studies of ICS in elderly patients failed to demon-
strate any increased risk of diabetes related to ICS expo-
sure.5,6 In a prospective cohort study of US veterans over 1
year, ICS exposure was associated with a dose-dependent
increase in serum glucose concentrations in patients with
established diabetes mellitus, but not in patients without
diabetes.7 Similarly, in a small, prospective, crossover
study in patients with established type 2 diabetes mellitus,
glycosylated haemoglobin levels rose significantly after 6
weeks of treatment with inhaled fluticasone.8 Together,
these observations suggest that ICS may exacerbate dia-
betes in asthma or COPD, by increasing blood glucose levels
in patients with established diabetes mellitus. Their impact
on incidence of diabetes mellitus, however, remains
uncertain.
The ICS budesonide first became available in the early
1980s and is also available as a fixed-dose combination with
the long-acting b2-agonist formoterol for the treatment of
asthma and COPD. The extensive clinical trial programme
conducted for budesonide provides a considerable pool of
patient data from which to examine the impact of ICS
therapy on a variety of patient outcomes, including the risk
for diabetes mellitus. The present pooled analysis was
undertaken to determine whether ICS increases the risk of
new onset diabetes mellitus or hyperglycaemia among
patients with asthma or COPD treated with budesonide
compared with those who did not receive budesonide in the
randomised controlled trials.Methods
Datasets
This study analysed data from all trials which used inhaled
budesonide, and were randomized, double blinded,involved patients 4 years of age, who had either asthma
or COPD, had a follow-up of more than 3 months (asthma)
or >6 months (COPD) and were fully completed by
December 2010.
Trials involving either placebo or active control thera-
pies were included. This comprised 26 double-blind,
placebo-controlled trials of budesonide or budesonide/
formoterol in patients with asthma (included in the
primary asthma dataset) (online repository Table), 34
double-blind active controlled trials of budesonide or
budesonide/formoterol in patients with asthma (combined
to give a total of 60 asthma trials in the secondary asthma
dataset), and 8 double-blind trials of budesonide-
containing products in patients with COPD, of which 7
were placebo-controlled (included in the COPD dataset)
(online repository Table). Three trials with a duration of >1
year were censored at 365 days to allow cross-comparisons
with other trials that were included in the analysis. Over-
all, the mean follow-up duration was 210 days in the 60
asthma trials and 268 days in the 8 COPD trials. The
number of steroid naı¨ve patients ranged from approxi-
mately 50% in the COPD trials, to between 0 and 100% in
the asthma trials. Diabetes mellitus was not an exclusion
criterion for any of these trials. The prevalence of diabetes
was <1% in all of the asthma trials and between 5 and 10%
in the COPD trials.
Outcome variables
Diabetes mellitus cases were identified as any adverse
event (AE) or serious adverse event (SAE) coded to the
MedDRA dictionary (version 13) as the term ‘Diabetes
mellitus (including subtypes)’; ‘Diabetic ketoacidosis’;
‘Diabetic hyperglycaemic coma’ or ‘Diabetic hyperosmolar
coma’. Hyperglycaemia cases were identified as any AE
(serious or non-serious) coded to the MedDRA dictionary
(version 13) as the terms ‘Hyperglycaemic conditions NEC’,
‘Blood glucose increased’, ‘Carbohydrate tolerance
decreased’, Glucose tolerance decreased, ‘Glucose toler-
ance test abnormal’ or ‘Glycosylated haemoglobin
increased’. Thus, diabetes AEs were defined as any new
onset diabetes mellitus or worsening of existing diabetes.
Patients with existing diabetes mellitus were not excluded,
as the AEs were examined post randomization to either ICS
or non-ICS treatment.
Statistical analysis
The risk of diabetes mellitus/hyperglycaemia as an AE or
SAE was compared between patients assigned to bude-
sonide or non-ICS treatments. KaplaneMeier curves were
generated to visually compare the time to the first re-
ported cases of diabetes mellitus/hyperglycaemia AEs
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Inhaled corticosteroids and diabetes mellitus 1489between treatment groups. Cox proportional hazards
regression modelling, both adjusted and not adjusted by
study, was used to estimate the relative risk of ICS on
time to the occurrence of diabetes mellitus/hyper-
glycaemia AEs. Hazard ratios (HRs) and the associated
95% confidence intervals (CIs) were calculated from these
models. In addition, a pooled relative risk (RR) was
calculated using a ManteleHaenszel approach stratified
by study, adjusted for treatment exposure, and
expressed as the pooled ManteleHaenszel RR and 95%
CIs. In the primary asthma dataset, a single trial, START,9
contributed the majority of patients (n Z 7221). As
a sensitivity analysis, the overall RR was calculated for
the START trial alone and for all trials in this dataset
excluding START.
We also determined a possible dose response by eval-
uating high versus low dose budesonide. For the dos-
eeresponse analysis in asthma, only trials that contained
a low-dose treatment arm as well as a high-dose treat-
ment arm were selected (14 trials), and for the budeso-
nide vs fluticasone comparison only trials involving both
ICS were selected (5 trials). We defined low dose as
budesonide of 320 mg/day delivered via Turbuhaler or
pressurised metered-dose inhaler (pMDI) or budesonide of
500 mg/day delivered as a nebulizing suspension. High
dose was defined as budesonide 640 mg/day via Tur-
buhaler or pMDI or 1000 mg/day as a nebulizing suspen-
sion. From the STAY trial,10 only adolescent and adult
patients from the budesonide/formoterol 160/9 mg/day
and the 640 mg/day treatment arms, respectively were
included in the doseeresponse analysis since in this study
the children 4e11 years of age received only half of these
doses. The comparisons of high-dose vs. low dose bude-
sonide, and of budesonide and fluticasone, were per-
formed using a ManteleHaenszel approach stratified by
study and adjusted for treatment exposure on a subset of
trials from the secondary asthma dataset. For the dos-
eeresponse analysis, only trials that contained a low-dose
treatment arm as well as a high-dose treatment arm were
analysed.
In the COPD dataset, a doseeresponse analysis was
conducted on the 3 studies which included two different
doses of a budesonide/formoterol (640/18 mg and
a 320/18 mg) using the ManteleHaenszel approach stratified
by study and adjusted for treatment exposure.
In both the secondary asthma and COPD datasets, risk
factor analyses using linear-tailed restricted cubic splines
in a Cox regression were used to model and adjust for
potential non-linearities for age, body mass index (BMI) and
baseline forced expiratory volume in 1 s (FEV1) expressed as
a percentage of predicted normal. Finally, as four studies in
the COPD dataset included the measurement of laboratory
safety data, an additional dataset was compiled consisting
of all patients for whom a baseline and end-of-treatment
blood glucose evaluation was available. These data were
analysed to determine the mean change from baseline to
end-of-treatment glucose levels for ICS- and non-ICS-
treated patients.
As this was a retrospective review of results from
a number of clinical trials, no approval was requested from
Research Ethics Committees from those institutions where
the data was collected.
Figure 1 KaplaneMeier survival curve describing the inci-
dence of diabetes mellitus/hyperglycaemia AE in patients in
the placebo-controlled asthma trials (budesonide vs. non-ICS:
HR 0.98; 95% CI: 0.38e2.50; p Z 0.96).
1490 P.M. O’Byrne et al.Results
The risk of new onset diabetes mellitus in patients
with asthma
The primary asthma dataset comprised 14,993 patients
with 8624 patient-years of exposure, while the secondary
asthma dataset included 33,496 patients exposed to bude-
sonide and 2773 patients exposed to fluticasone. In the
asthma dataset, the mean age was 34.4 years, mean BMI
was 24.9 kg/m2 and mean baseline FEV1 was 82% predicted
normal.
In the primary asthma dataset, the incidence of diabetes
mellitus/hyperglycaemia AEswas 0.13% (nZ 12; rate 2.5 perFigure 2 KaplaneMeier survival curve describing the inci-
dence of diabetes mellitus/hyperglycaemia AE in patients in
the COPD trials (budesonide vs. non-ICS: HR 0.99; 95% CI:
0.67e1.46; p Z 0.96).1000 treatment years [TTY]) among patients randomised to
budesonide and 0.13% (n Z 8; 2.1 per TTY) among those
randomised to non-ICS (Table 1); diabetes mellitus/hyper-
glycaemia as an SAE were reported by 0% of patients with
asthma (nZ 0) randomised to budesonide and 0.08% (nZ 3;
0.8 per TTY) of those randomised to non-ICS. In addition, the
time to first diabetes mellitus/hyperglycaemia AE was not
significantly different between budesonide- and non-ICS-
treated asthma patients (HR 0.98; 95% CI: 0.38e2.50;
p Z 0.96) (Fig. 1). The overall ManteleHaenzel RR for the
reporting of diabetes mellitus/hyperglycaemia as an AE was
not statistically significantly different between asthma
patients randomised to budesonide and those randomised to
non-ICS (ManteleHaenzel RR 1.02; 95% CI: 0.42e2.53;
p Z 0.96). No statistically significant differences emerged
when the results were analysed separately for the START
study (ManteleHaenzel RR 1.22; 95% CI: 0.33e4.53;
p Z 0.77) or for all trials except START (RR 0.87; 95% CI:
0.25e3.04; p Z 0.82). In the secondary asthma dataset,
diabetes mellitus/hyperglycaemia was reported as an AE by
0.19% (nZ 65; 3.0 per TTY) and as an SAE by 0.03% (nZ 6; 0.3
per TTY) of patients randomised to budesonide. There was
no statistically significant difference in the exposure
adjusted RR, stratified by trial, for high-dose versus low-dose
budesonide (RR 2.56; 95% CI: 0.49e13.4), or for budesonide
versus fluticasone (RR 0.44; 95% CI: 0.12e1.62) in the active
treatment-controlled asthma trials.
The risk of new onset diabetes mellitus in patients
with COPD
The COPD dataset included 8259 patients with 6070
patient-years of exposure. In this dataset the mean ageFigure 3 Forest plot of the risk ratio for reporting diabetes
mellitus/hyperglycaemia as an AE in the COPD trials. The size
of the boxes reflects the number of patients included in the
trial.
Figure 4 Univariate spline modelling of hazard ratio (HR) of diabetes mellitus/hyperglycaemia AEs by: (A) age (normalised to age
35 years for asthma, 65 years for COPD); (B) BMI (normalised to BMI of 25 kg/m2 for asthma and COPD); and (C) disease severity
(baseline FEV1; normalised to FEV1 100% of predicted normal for asthma, FEV1 50% of predicted normal for COPD) among asthma
and COPD patients exposed to budesonide. The solid line gives the HR over the predictor range and the dashed lines indicate the
corresponding 95% CIs.
Inhaled corticosteroids and diabetes mellitus 1491
1492 P.M. O’Byrne et al.was 61.8 years, mean BMI was 25.9 kg/m2 and mean
baseline FEV1 was 49% of predicted normal. The incidence
of diabetes mellitus/hyperglycaemia AEs was 1.3% (nZ 63;
rate 18.5 per TTY) among patients randomised to budeso-
nide and 1.2% (n Z 44; 16.5 per TTY) among those rand-
omised to non-ICS therapy; diabetes mellitus/
hyperglycaemia as an SAE was reported by 0.1% of COPD
patients (n Z 5; 1.5 per TTY) randomised to budesonide
and 0.03% (nZ 1; 0.4 per TTY) of those randomised to non-
ICS treatment (Table 1). The time to first diabetes melli-
tus/hyperglycaemia AE was not significantly different
between budesonide- and non-ICS-treated patients (HR
0.99; 95% CI: 0.67e1.46; p Z 0.96) (Fig. 2). The overall
ManteleHaenzel RR for the reporting of diabetes mellitus/
hyperglycaemia as an AE was similar between those rand-
omised to budesonide and those randomised to non-ICS
treatment (ManteleHaenzel RR 0.94; 95% CI: 0.65e1.37;
p Z 0.74) (Fig. 3).
In the COPD and secondary asthma datasets, the risk for
diabetes mellitus/hyperglycaemia increased with age, BMI
and disease severity as measured by baseline FEV1 (Fig. 4).
Additionally, in 4 trials of the COPD dataset, there was no
statistically significant change from baseline to end-of-
treatment in non-fasted blood glucose levels for budeso-
nide- versus non-ICS-treated patients. The mean [SD]
baseline blood glucose was 5.80  1.72 mmol/L for
budesonide-treated and 5.77  1.89 mmol/L for non-ICS
treated patients. The mean change from baseline to end-
of treatment was þ0.12 mmol/L for budesonide-treated
and þ0.13 mmol/L for non-ICS treated patients (differ-
ence 0.008 mmol/L; p Z 0.88) (Fig. 5).
In the COPD dataset there was no evidence of a higher
risk for diabetes mellitus/hyperglycaemia AEs for high-dose
versus low-dose budesonide (RR 0.67; 95% CI: 0.37e1.22;
p Z 0.20).Figure 5 Individual blood glucose (mmol/L) at baseline and
at end of treatment for: (A) ICS-treated (n Z 2929), and (B)
non-ICS-treated COPD patients (n Z 2060).Discussion
These analyses of all of the clinical trials of the ICS,
budesonide, did not identify any increased risk of new
onset diabetes mellitus or hyperglycaemia (reported as an
AE or SAE) in patients with asthma or with COPD. They also
did not identify a difference in these outcomes for high
versus low dose ICS. Furthermore, in four large clinical
trials in COPD in which glucose measurements were per-
formed, ICS did not modify blood glucose concentrations.
Together, these data do not support a link between ICS (in
the doses employed in these studies) and new onset dia-
betes mellitus in asthma or COPD patients.
Systemic corticosteroids are associated with insulin
resistance and hyperglycaemia. Therefore, it might be
anticipated that inhaled corticosteroids, particularly at
high doses, might also result in hyperglycaemia. Suissa
et al.4 have reported, in a large nested case-controlled
study, that ICS exposure was associated with an increase
in the risks of diabetes onset and diabetes progression.
However, others have only been able to show an effect of
ICS on blood sugar in patients already treated for diabetes7
and Dendukuri et al.6 did not find any association of dia-
betes (identified by its treatment with medications) with
the dispensing of ICS. The main limitation of these otherstudies was that they were observational in nature and
could not account for measured and unmeasured factors
that may have distorted the findings such as confounding by
indication (i.e sicker patients with co-morbidities including
diabetes may have been more likely to have received ICS)
or reverse confounding (i.e as sicker patients are more
likely to have co-morbidities including diabetes, ICS may
have been avoided in such patients). The major strength of
the present study was that it evaluated data from large
randomized controlled trials and analysed based on
intention-to-treat, which mitigated the risk of confounding.
The other major strength of the present study was the
large sample size, which afforded robust statistical power
Inhaled corticosteroids and diabetes mellitus 1493to detect small, but clinically relevant, differences
between ICS exposed and non-exposed patients with
asthma or COPD. The large sample size also provided
a unique opportunity to evaluate risk factors for diabetes
mellitus in these respiratory populations. We found that the
risk for diabetes mellitus/hyperglycaemia AEs in budeso-
nide treated patients with asthma or COPD increased with
increasing age, increasing BMI and increasing asthma or
COPD severity, as measured by decreasing baseline FEV1.
The significant increases in risk observed in this part of the
analysis for age and BMI have been well established.
However, the increased risk for low baseline FEV1 is novel.
This study was not designed to determine the mechanisms
or a cause and effect relationship behind this association.
Future studies will be needed to explore this relationship in
depth.
There were limitations to the present study. First, the
baseline risk and number of cases of diabetes was low and
the confidence intervals were wide enough to have missed
a clinically important effect of ICS on the risk of diabetes.
Second, we did not have biochemical validation of dia-
betes. Thus, case misclassification was possible, which
would have diluted the results. Third, the follow-up was
relatively short. As ICS are recommended as maintenance
therapy, future studies will be needed to evaluate the long-
term effects of ICS on these endpoints. Finally, the patients
included in this pooled analysis were, for the most part,
free of any significant co-morbidities. Thus, we could not
determine the possible effect of ICS on diabetes in patients
with multiple co-morbidities.
Notwithstanding these limitations, the present analyses
suggest that, in contrast to regular oral corticosteroid use,
1 year of ICS treatment does not increase the risk of new
onset diabetes or hyperglycemia.
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